

NCT ID	NCT03994601
Title	An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Phase	Phase 1
Date Added	2019-06-21
Location	California, United States Colorado, United States Maryland, United States Missouri, United States New Jersey, United States Argentina Canada Chile France Italy Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	BMS-986288, Nivolumab, Opdivo
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03970382
Title	A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Phase	Phase 1
Date Added	2019-05-31
Location	California, United States Illinois, United States New York, United States Tennessee, United States Washington, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Suspended
Drugs	IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab
Tags	MSS/ MMRp
NCT ID	NCT03983993
Title	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2019-06-12
Location	Georgia, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Niraparib, panitumumab, Vectibix, Zejula
Tags	MSS/ MMRp
NCT ID	NCT03745326
Title	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Phase	Phase 1, Phase 2
Date Added	2018-11-19
Location	Maryland, United States

Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03280511
Title	Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
Phase	Phase 2
Date Added	2017-09-12
Location	Denmark
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	PIPAC
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05141474
Title	Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Phase	Early Phase 1
Date Added	2021-12-02
Location	Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05215574
Title	Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-01-31
Location	Arizona, United States California, United States Florida, United States Michigan, United States New York, United States Oklahoma, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	NGM831, NGM831 plus pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04332653
Title	NT-17 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2020-04-03

Location	Florida, United States Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Completed
Drugs	NT-17, Pembrolizumab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03851614
Title	Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
Phase	Phase 2
Date Added	2019-02-22
Location	Canada
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Cediranib, durvalumab, Olaparib
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03832855
Title	Assessing the Immunogenicity of pING-hHER3FL
Phase	Phase 1
Date Added	2019-02-06
Location	North Carolina, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	pING-hHER3FL
Tags	MSI-H/ MMRd, MSS/ MMRp